Laahn Foster, MD

Discover the latest FDA-approved therapy for high-risk smoldering myeloma, enhancing early intervention strategies and patient care discussions.

Explore the evolving landscape of smoldering myeloma treatment, focusing on fixed-duration therapy and patient-provider communication strategies.

Explore the latest findings on smoldering myeloma treatments, including lenalidomide's effectiveness and the importance of patient monitoring in clinical trials.

Daratumumab shows promise in managing smoldering myeloma, balancing infection risks and adverse effects while offering a preferable alternative to lenalidomide.

Experts discuss the impact of daratumumab on smoldering myeloma, exploring survival rates, treatment options, and the importance of clinical trials.

Explore the AKELA trial's findings on patient characteristics and the impact of daratumumab on progression-free survival in myeloma treatment.

The AQUILA trial explores a fixed-duration therapy for myeloma, aiming to balance effective treatment with reduced long-term toxicity for patients.

Early intervention in myeloma treatment addresses critical patient needs, highlighting new trial data and the importance of tailored therapies for better outcomes.

Explore the evolving landscape of high-risk smoldering myeloma treatment options and the challenges in patient management and risk assessment.

Explore the evolving treatment strategies for high-risk smoldering multiple myeloma, emphasizing early intervention and recent clinical advancements.